Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-678 in Relapsed/Refractory CML-AP
NCT06453902Phase 2Recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TGRX-678 in chronic myeloid leukemia (CML), sponsored by Shenzhen TargetRx. Started Jul 2024; status: recruiting.
02
Drugs
TGRX-678
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06453902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453902.